RNA gene therapy raises survival rate for cancer patients with complications to 90%... clinical trials planned for 2030

KAIST researchers developed an RNA-based antisense oligonucleotide therapy that suppresses GFRAL, a key receptor driving cancer cachexia.

In animal studies, the treatment reduced muscle and fat loss, improved metabolic abnormalities, and significantly boosted survival.

The findings were published in Cell Reports Medicine, and KAIST with Tor Therapeutics is advancing CMC and nonclinical studies toward clinical entry.

The team aims to begin patient trials by 2030.